Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Agios Pharmaceuticals, Inc.

AGIO Nasdaq Pharmaceutical Preparations Financials FY2016โ€“FY2025

Last close ยท Oct 23, 2026

$37.00

0.5%
Compare
Revenue Total sales reported in the income statement.
$54.0M
48.0% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’873.9%
292.6ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$413M
161.3%
Free cash flow Cash from operations minus capital spending.
โˆ’$377M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$2.2B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$7.02 EPS (TTM)

What Agios Pharmaceuticals, Inc. does

No business description yet.

Legal name
AGIOS PHARMACEUTICALS, INC.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Feb 12, 2026
Accession ยท CIK
0001439222-26-000025
0001439222

Revenue and margins

Agios Pharmaceuticals, Inc. had $54.0M of revenue in fiscal 2025, up 48.0% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$377M in fiscal 2025, โˆ’698.3% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Agios Pharmaceuticals, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 0.1%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Agios Pharmaceuticals, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $1.0B$783M$777M$894M$854M
Current ratio 17.8x13.3x12.3x11.9x11.5x
Quick ratio 17.8x13.2x12.0x11.6x11.1x
Total assets $1.4B$1.2B$937M$1.7B$1.3B
Total liabilities $146M$138M$126M$122M$104M
Shareholders' equity $1.3B$1.1B$811M$1.5B$1.2B
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ“ โœ• โœ• โœ“ โœ•
Cash from operations is positive โœ“ โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ• โœ“ โœ• โœ“ โœ“ โœ• โœ• โœ“ โœ•
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“ โœ• โœ• โœ“ โœ• โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ• โœ“ โœ“ โœ“ โœ“ โœ• โœ• โœ• โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ“ โœ“ โœ• โœ• โœ•
Gross margin rose โ€” โœ• โœ• โœ“ โ€” โ€” โ€” โœ“ โœ• โœ•
Revenue rose relative to assets โ€” โœ• โœ“ โœ“ โœ• โœ• โœ“ โœ“ โœ• โœ“
F-score โ€” / 31 / 84 / 84 / 83 / 74 / 72 / 73 / 82 / 82 / 8
Accruals ratio โˆ’38.3%โˆ’4.8%โˆ’5.6%โˆ’4.7%โˆ’4.2%175.7%5.8%โˆ’5.1%81.8%โˆ’2.7%
Altman Z'' 1.72โˆ’2.351.17โˆ’1.43โˆ’4.6011.589.116.4514.7112.52

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $69.9M $43.0M $94.4M $118M $0.0M $0.0M $14.2M $26.8M $36.5M $54.0M
Gross profit $69.9M $43.0M $93.0M $117M $0.0M $0.0M $12.5M $23.9M $32.3M $47.7M
Research and development $220M $293M $341M $214M $221M $257M $280M $296M $301M $340M
Operating income โˆ’$201M โˆ’$321M โˆ’$362M โˆ’$316M โˆ’$336M โˆ’$378M โˆ’$389M โˆ’$391M โˆ’$426M โˆ’$472M
Pretax income โˆ’$198M โˆ’$315M โˆ’$346M โˆ’$301M โˆ’$329M โˆ’$357M โˆ’$232M โˆ’$352M $718M โˆ’$414M
Income tax $0.0M $0.0M $0.0M $0.0M โ€” โ€” $0.0M $0.0M $44.2M โˆ’$1.0M
Net income โˆ’$198M โˆ’$315M โˆ’$346M โˆ’$411M โˆ’$327M $1.6B โˆ’$232M โˆ’$352M $674M โˆ’$413M
Diluted EPS โˆ’$5.07 โˆ’$6.75 โˆ’$6.03 โˆ’$6.86 โˆ’$4.74 $26.55 โˆ’$4.23 โˆ’$6.33 $11.64 โˆ’$7.12
Diluted shares 0.04B 0.05B 0.06B 0.06B 0.07B 0.06B 0.05B 0.06B 0.06B 0.06B
Cash flow
Cash from operations $38.6M โˆ’$285M โˆ’$304M โˆ’$371M โˆ’$291M โˆ’$407M โˆ’$309M โˆ’$296M โˆ’$390M โˆ’$373M
Capital expenditure $9.9M $4.6M $7.0M $12.0M $14.1M $5.7M $4.9M $1.0M $1.7M $4.3M
Free cash flow $28.6M โˆ’$290M โˆ’$311M โˆ’$383M โˆ’$305M โˆ’$413M โˆ’$314M โˆ’$297M โˆ’$392M โˆ’$377M
Depreciation and amortization $5.7M $6.4M $7.2M $8.1M $9.4M $8.8M $8.4M $6.6M $5.7M $5.2M
Stock-based compensation $42.1M $47.8M $73.4M $58.1M $61.6M $53.5M $49.3M $44.8M $42.8M $52.6M
Balance sheet
Cash and short-term investments $541M $103M $585M $565M $573M $1.0B $783M $777M $894M $854M
Current assets $560M $445M $614M $612M $637M $1.1B $833M $834M $966M $942M
Current liabilities $88.4M $94.9M $93.5M $92.9M $94.4M $59.8M $62.6M $68.0M $81.2M $82.2M
Inventory โ€” $0.0M $0.9M $7.3M $14.7M $0.0M $8.5M $19.1M $27.6M $32.9M
Property and equipment, net $25.3M $24.4M $24.3M $31.5M $30.8M $28.9M $23.0M $15.4M $11.7M $10.8M
Total assets $619M $614M $858M $891M $853M $1.4B $1.2B $937M $1.7B $1.3B
Total liabilities $261M $239M $171M $250M $453M $146M $138M $126M $122M $104M
Preferred stock $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M โ€” โ€” โ€” โ€”
Shareholders' equity $359M $376M $688M $641M $400M $1.3B $1.1B $811M $1.5B $1.2B
Margins
Gross margin 100.0% 100.0% 98.5% 98.9% โ€” โ€” 88.0% 89.3% 88.6% 88.3%
Operating margin โˆ’287.6% โˆ’745.8% โˆ’384.0% โˆ’268.2% โ€” โ€” โˆ’2,732.1% โˆ’1,459.5% โˆ’1,166.5% โˆ’873.9%
EBITDA margin โˆ’279.4% โˆ’730.9% โˆ’376.4% โˆ’261.4% โ€” โ€” โˆ’2,673.1% โˆ’1,434.9% โˆ’1,150.8% โˆ’864.2%
Net margin โˆ’284.0% โˆ’731.6% โˆ’366.6% โˆ’349.0% โ€” โ€” โˆ’1,627.8% โˆ’1,312.6% 1,845.9% โˆ’764.0%
FCF margin 41.0% โˆ’673.9% โˆ’329.9% โˆ’324.5% โ€” โ€” โˆ’2,207.6% โˆ’1,107.5% โˆ’1,072.7% โˆ’698.3%
Returns
Return on capital employed โˆ’37.9% โˆ’61.8% โˆ’47.4% โˆ’39.6% โˆ’44.3% โˆ’27.5% โˆ’33.1% โˆ’45.0% โˆ’26.9% โˆ’38.9%
Return on equity โˆ’55.3% โˆ’85.7% โˆ’65.1% โˆ’62.0% โˆ’63.0% 189.7% โˆ’19.4% โˆ’36.8% 57.3% โˆ’30.2%
Return on assets โˆ’32.1% โˆ’51.0% โˆ’47.0% โˆ’47.0% โˆ’37.5% 140.1% โˆ’17.3% โˆ’32.4% 51.8% โˆ’27.9%
Return on tangible equity โˆ’55.3% โˆ’83.8% โˆ’50.3% โˆ’64.2% โˆ’81.9% 124.2% โˆ’21.1% โˆ’43.4% 43.7% โˆ’34.6%
Growth
Revenue growth โ€” โˆ’38.5% 119.4% 24.9% โˆ’100.0% โ€” โ€” 88.4% 36.1% 48.0%
Net income growth โ€” โ€” โ€” โ€” โ€” โ€” โˆ’114.4% โ€” โ€” โˆ’161.3%
EPS growth โ€” โ€” โ€” โ€” โ€” โ€” โˆ’115.9% โ€” โ€” โˆ’161.2%
FCF growth โ€” โˆ’1,111.8% โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Share count change โ€” 19.1% 23.2% 4.5% 15.0% โˆ’12.4% โˆ’9.4% 1.6% 4.0% 0.1%
Financial health
Current ratio 6.3x 4.7x 6.6x 6.6x 6.7x 17.8x 13.3x 12.3x 11.9x 11.5x
Quick ratio 6.3x 4.7x 6.6x 6.5x 6.6x 17.8x 13.2x 12.0x 11.6x 11.1x
Capital allocation
Capex / revenue 14.2% 10.8% 7.4% 10.2% โ€” โ€” 34.3% 3.7% 4.6% 8.0%
Stock comp / revenue 60.2% 111.2% 77.7% 49.2% โ€” โ€” 346.2% 166.9% 117.4% 97.3%
Quality scores
Piotroski F-score โ€” 1.0 4.0 4.0 3.0 4.0 2.0 3.0 2.0 2.0
Altman Z'' 1.7 โˆ’2.4 1.2 โˆ’1.4 โˆ’4.6 11.6 9.1 6.4 14.7 12.5
Accruals ratio โˆ’38.3% โˆ’4.8% โˆ’5.6% โˆ’4.7% โˆ’4.2% 175.7% 5.8% โˆ’5.1% 81.8% โˆ’2.7%

Source: SEC EDGAR XBRL filings (CIK 0001439222). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open